151. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach.
- Author
-
Lutgendorf SK, Mullen-Houser E, Russell D, Degeest K, Jacobson G, Hart L, Bender D, Anderson B, Buekers TE, Goodheart MJ, Antoni MH, Sood AK, and Lubaroff DM
- Subjects
- Adult, Affect physiology, Aged, Aged, 80 and over, Combined Modality Therapy, Erythrocyte Count, Female, Humans, Killer Cells, Natural physiology, Leukocyte Count, Middle Aged, Prospective Studies, Quality of Life, Relaxation physiology, Relaxation Therapy, Social Support, Socioeconomic Factors, Treatment Outcome, Uterine Cervical Neoplasms psychology, Young Adult, Antineoplastic Agents adverse effects, Complementary Therapies, Radiotherapy adverse effects, Therapeutic Touch, Uterine Cervical Neoplasms immunology, Uterine Cervical Neoplasms therapy
- Abstract
Patients receiving chemoradiation for cervical cancer are at risk for distress, chemoradiation-related side-effects, and immunosuppression. This prospective randomized clinical trial examined effects of a complementary therapy, Healing Touch (HT), versus relaxation training (RT) and usual care (UC) for (1) supporting cellular immunity, (2) improving mood and quality of life (QOL), and (3) reducing treatment-associated toxicities and treatment delay in cervical cancer patients receiving chemoradiation. Sixty women with stages IB1 to IVA cervical cancer were randomly assigned to receive UC or 4 ×/weekly individual sessions of either HT or RT immediately following radiation during their 6-week chemoradiation treatment. Patients completed psychosocial assessments and blood sampling before chemoradiation at baseline, weeks 4 and 6. Multilevel regression analyses using orthogonal contrasts tested for differences between treatment conditions over time. HT patients had a minimal decrease in natural killer cell cytotoxicity (NKCC) over the course of treatment whereas NKCC of RT and UC patients declined sharply during chemoradiation (group by time interaction: p = 0.018). HT patients showed greater decreases in two different indicators of depressed mood (CES-D depressed mood subscale and POMS depression scale) compared to RT and UC (group by time interactions: p<0.05). No between group differences were observed in QOL, treatment delay, or clinically-rated toxicities. HT may benefit cervical cancer patients by moderating effects of chemoradiation on depressed mood and cellular immunity. Effects of HT on toxicities, treatment delay, QOL, and fatigue were not observed. Long-term clinical implications of findings are not known., (Copyright © 2010 Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF